China
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, today announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. DB-1305 is currently in a Phase 1/2 clinical trial (NCT05438329) for solid tumors.
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it has entered into a purchase agreement with a select group of institutional and accredited healthcare specialist investors for the private placement of (i) 138,900,000 ordinary shares of the Company (the "Ordinary Shares") (equivalent to 27,780,000 of the Company's American depositary shares ("ADSs")), at a purchase price equivalent to $3.60 per ADS, and (ii) warrants to purchase up to 44,802,870 Ordinary Shares (equivalent to 8,960,574 ADSs) (the "Warrants") at an exercise price equivalent to $5.58 per ADS, representing a 55% premium to the purchase price of Ordinary Shares.
Hong Kong-based biotech Insilico Medicine shifts IPO plan to city from New York
Hong Kong-based biotech company Insilico Medicine has set its sights on an initial public offering in the city, shelving its earlier New York fundraising plan, as the start-up seeks capital to finance clinical trials of drugs discovered and designed by artificial intelligence.
Qiming-Backed AI Drug Discovery Startup Insilico Medicine Files For Hong Kong IPO
Insilico Medicine, a Hong Kong and New York-based company that uses AI for drug discovery, has filed for an initial public offering in the Asian financial hub that’s slowly recovering from a drought of major listings.
China’s CanSino in mRNA vaccine deal with AstraZeneca
CanSino Biologics (6185.HK) has agreed with AstraZeneca (AZN.L) to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.
Hong Kong removes requirement to flag China risk in listing applications
Hong Kong stock exchange has removed a China-risk section for mainland-incorporated companies in its listing application rules with effect from Tuesday, which the bourse said was to align disclosure requirements for IPO-aspirants from other countries and the scrutiny level remains the same.
Biden order proposes new restrictions on China tech investment
President Biden signed an executive order Wednesday aimed at curbing the flow of U.S. investment and management know-how into a limited range of Chinese firms that the administration fears could fuel Beijing’s military ambitions.
China’s medical exports tumble as world moves on from COVID
China's medical exports fell 26.1% year-on-year in the first half of 2023, dragged down by weaker demand amid a sluggish global economic recovery and a high base for comparison.
Baird Medical Submits Disposable Microwave Ablation Needle and MWA System Application to U.S. FDA for Treatment of Soft Tissue Microwave Ablation
Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced the 510(k) premarket notification submission of the Company's Disposable Microwave Ablation ("MWA") Needle and the Company's MWA System to the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue microwave ablation.
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of atopic dermatitis.
